LeanBio

SME

LeanBio

Description

The entity profile has not yet been completed.

This entity is yours?
Sign in to update information and position your organization seamlessly within the European bioproduction Value Chain. Benefit from the geolocated map to showcase your expertise, projects, and initiatives. Boost your visibility and make meaningful connections within the ecosystem. Sign in

LeanBio

Address

Barcelona, Catalunya, Spain

Contact

contact@leanbiopro.com

Description

The entity profile has not yet been completed.

This entity is yours?
Sign in to update information and position your organization seamlessly within the European bioproduction Value Chain. Benefit from the geolocated map to showcase your expertise, projects, and initiatives. Boost your visibility and make meaningful connections within the ecosystem.

Matchmaking

Connect with LeanBio

Position on the value chain

With the ultimate aim to create a European alliance for bioproduction in Europe, organisations have joined forces with COBIOE. Discover who are our associates.

Bio-resources and biobanking
  • Cells, tissues and humanized xeno-organs
  • Biosamples
  • Viral, phage or bacterial specimen
Identification of biotherapies
  • Target identification
  • Target validation
  • Screening
Drug design
  • Drug assessment
  • Drug engineering
  • In vitro preclinical studies
Clinical validation
  • Clinical trials
  • In vivo preclinical validation
  • Pre-industrial scale production
Production
  • Upstream processes
  • Downstream processes
  • Quality control
Market access
  • CE mark / market authorisation
  • Payment / Reimbursement
  • Care pathways

LeanBio last news

29/12/2023

Leanbio amplía en 20 millones su inversión en la nueva planta de Sant Quirze del Vallès | Revista Digital del Vallès

[...] Leanbio una empresa que proporciona servicios integrales de desarrollo y fabricación de productos biológicos para los sectores farmacéutico y biofarmacéutico ha informado que añade 20 millones de euros de inversión a su planta, actualmente en construcción, de San [...]

26/12/2023

Leanbio elevará a 30 millones la inversión en la nueva planta de Sant Quirze del Vallès

[...] El ecosistema biotech barcelonés suma una nueva gran instalación entre sus actores destacados. La empresa biotecnológica Leanbio, fundada en 2014 en Barcelona, alcanza su décimo aniversario con la necesidad de ampliar su capacidad productiva para el desarrollo [...]

21/12/2023

Charles River to make Casgevy; Rentschler extends collab with 'major client'; Andelyn works with Ultragenyx

Welcome to Endpoints News' manufacturing news briefs, where we bring you essential updates on new builds, collaborations, recalls and more. Charles River Laboratories said Monday it will manufacture Vertex and CRISPR Therapeutics' Casgevy, with its Memphis site having gone through audits by the FDA and EMA. CDMO RoslinCT also manufactures the gene editing therapy. CDMO Rentschler Biopharma said that it has a " major client " for its manufacturing site in Milford, MA, with the facility set to go live in the second half of next year. The manufacturer noted Wednesday it will produce its "longstanding" client's clinical-stage protein therapeutic for cancer in the US, after previously producing the same asset in Laupheim, Germany, for early-phase investigation. CDMO Andelyn Biosciences announced that it will manufacture process performance qualification batches for Ultragenyx's late-stage AAV9 gene therapy, dubbed UX111, for Sanfilippo syndrome type A. "We have successfully transferred the UX111 GMP process to our commercial manufacturing facility in Columbus, Ohio," Andelyn CCO Matt Niloff said in a Monday press release. The PPQ batches will be needed for potential future regulatory applications. CDMO Agno Pharma on Monday revealed that it will acquire the drug product formulation company Lubrizol Particle Sciences  in a deal that allows the manufacturer to absorb its drug product formulation tech and a facility in Bethlehem, PA, with about 65 staffers. CDMO Leanbio said it is allocating an additional €20 million ($22 million) to expand a facility being built near Barcelona. The site will have three production lines to produce plasmid DNA and messenger RNA, as well as recombinant proteins and antibodies, the company said Tuesday. CDMO Piramal Pharma opened the extension to its antibody-drug conjugate manufacturing site in Grangemouth, Scotland, earlier this week. The £45 million ($57 million) expansion gives the site two additional manufacturing suites on top of the first three suites. Drug container and delivery system company Schott Pharma said Tuesday that it ended its 2023 fiscal year with €899 million ($987.9 million) in revenue, which is up 9% versus €821 million ($902 million) in the previous year. On Wednesday, the company said that its new site in Jagodina, Serbia, would create more than 100 jobs. Raw material supplier Biosynth acquired chemical R&D company VIO Chemicals for an undisclosed amount, the companies revealed Tuesday.